A Selective Biligand Inhibitor of CK2 Increases Caspase‐3 Activity in Cancer Cells and Inhibits Platelet Aggregation
Sign Up to like & getrecommendations! Published in 2017 at "ChemMedChem"
DOI: 10.1002/cmdc.201700457
Abstract: Cancer cells express high levels of CK2, and its inhibition leads to apoptosis. CK2 has therefore emerged as a new drug target for cancer therapy. A biligand inhibitor ARC‐772 was constructed by conjugating 4‐(2‐amino‐1,3‐thiazol‐5‐yl)benzoic acid… read more here.
Keywords: cancer; biligand inhibitor; ck2; cancer cells ... See more keywords